Core Viewpoint - The synthetic biology industry is rapidly developing in China, supported by government policies, and is expected to become a new golden track for investment opportunities [1][2]. Industry Overview - Synthetic biology is recognized as one of the most transformative technologies in the life sciences of the 21st century, with various regions in China, including Shenzhen, prioritizing its development [2]. - The domestic synthetic biology technology sector was in its early stages in 2017, with limited recognition of its application value [2]. Company Profile - Shenzhen Ruidelin Biotechnology Co., Ltd. focuses on synthetic biology technology and has developed over 200 patents related to biosynthetic active ingredients, serving more than 2,000 enterprises [1][3]. - The company aims to address industry pain points by utilizing biosynthetic technology to reduce costs and increase production capacity for peptides [2][3]. Technological Innovation - Ruidelin has established a multidisciplinary green biotechnology manufacturing platform that integrates various engineering disciplines, enhancing research and development efficiency [4]. - The company has incorporated artificial intelligence into enzyme engineering, creating over 50 AI models to optimize enzyme performance, which significantly improves research efficiency [5]. Production Capacity - Ruidelin has invested nearly 200 million yuan to build a green active ingredient smart factory, which includes two hundred-ton production lines and has successfully scaled up production of various products [7]. - The company is constructing a thousand-ton production base in Shaoguan, Guangdong, expected to produce over 1,000 tons of green active ingredients annually, generating more than 2 billion yuan in annual output value [7]. Financial Performance - Since 2022, Ruidelin has experienced continuous revenue growth, with projected revenue exceeding 100 million yuan in 2024 [8].